Biomarkers and surrogate criteria: preferred definitions and conceptual framework.
Clin Pharmacol Ther. 2001; 69: 89-95
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
N Engl J Med. 2001; 345: 1091-1097
Disease-free survival versus overall survival as the primary endpoint of adjuvant colon cancer studies: individual data from 20,898 patients from 18 randomized trials.
J Clin Oncol. 2005; 23: 8664-8670
Two- or three-year disease-free survival (DFS) as primary endpoint in adjuvant stage III colon cancer trials of fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT , PETACC-3, C-06, C-07 and C89803.
Eur J Cancer. 2011; 47: 990-996
Randomized multicentre trial of fluorouracil and folinic acid adjuvant compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
J Clin Oncol. 2006; 24: 4976-4982
Uracil-tegafur oral adjuvant with leucovorin for colorectal cancer liver metastases: a randomized controlled trial.
PLoS One. 2016; 11e0162400
Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for hepatic-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial.
J Clin Oncol. 2021; 39: 3789-3799
A randomized phase III study comparing the adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients after complete resection of hepatic metastases from colorectal cancer.
Anne Oncol. 2009; 20: 1964-1970
Disease-free survival as a putative surrogate for overall survival in phase III trials of curative treatment of colorectal liver metastases: a systematic review.
World J Clin Oncol. 2017; 8: 266-272
Adjuvant chemotherapy may prolong disease-free survival but did not influence the type of disease recurrence or subsequent treatment in patients with colorectal liver metastases.
Operation. 2021; 170: 1151-1154
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the ACCENT dataset of 20,800 patients.
J Clin Oncol. 2010; 28: 460-465
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the PUMP multicenter randomized controlled trial.
BMC Cancer. 2019; 19: 327
Surrogate endpoints in clinical trials: definition and operational criteria.
StatMed. 1989; 8: 431-440
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial.
Lancet. 2008; 371: 1007-1016
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results from a randomized, controlled phase 3 trial.
Lancet Oncol. 2013; 14: 1208-1215
PRISMA 2020 reporting: an updated guideline for reporting systematic reviews.
BMJ. 2021; 372: n71
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
N Engl J Med. 1999; 341: 2039-2048
The I(2) heterogeneity statistic may be biased in small meta-analyses.
Methodology BMC Med Res. 2015 ; 15: 35
Recurrence after partial hepatectomy for metastatic colorectal cancer: potentially curative role of salvage resection.
Ann Surg Oncol. 2015 ; 22: 2761-2771
Practical methods for incorporating summary time-to-event data into meta-analysis.
Trials. 2007; 8: 16
Comparison of adjuvant systemic chemotherapy with or without chemotherapy by hepatic arterial infusion after hepatic resection for metastatic colorectal cancer.
Anne Surg. 2011; 254: 851-856
Combined modality treatment of resectable metastatic colorectal carcinoma to the liver: surgical resection of liver metastases in combination with continuous infusion of chemotherapy – an intergroup study.
J Clin Oncol. 2002; 20: 1499-1505
What are the goals of patients and oncologists when starting medical treatment for metastatic lung cancer?.
Lung cancer clink. 2021; 22: 242-251
Life and treatment goals of patients with advanced and incurable cancer.
Cancer Care Support. 2016; 24: 2953-2962
Associations between prognostic understanding, quality of life and mood in patients with advanced cancer.
Cancer. 2014 ; 120: 278-285
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.
Biom J. 2016; 58: 104-132
Difference between disease-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure.
Ann Surg Oncol. 2014 ; 21: 1817-1824
Trends in long-term survival after hepatic resection for hepatic colorectal metastases.
Anne Surg. 2002; 235: 759-766
The disease-free interval between resection of a primary colorectal malignancy and detection of liver metastases predicts disease recurrence but not overall survival.
Ann Surg Oncol. 2019; 26: 2812-2820
Five years of cancer drug approvals: innovation, efficacy and costs.
JAMA Oncol. 2015 ; 1: 539-540
Phase III study comparing bevacizumab and docetaxel with placebo and docetaxel for the first-line treatment of metastatic breast cancer at human epidermal growth factor receptor 2.
J Clin Oncol. 2010; 28: 3239-3247
RIBBON-1: randomized, double-blind, placebo-controlled trial of chemotherapy with or without bevacizumab (B) for the first-line treatment of locally recurrent or metastatic HER2-negative breast cancer (MSC).
Proc Am Soc Clin Oncol. 2009; 27 1005
A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MSC).
Proc Am Soc Clin Oncol. 2010; 28 1005
Reputation and precedent in the bevacizumab decision.
N Engl J Med. 2011; 365: e3
Predictors of early recurrence after hepatectomy for initially unresectable colorectal liver metastases.
J Gastrointest Surg. 2013; 17: 939-948
Early recurrence after hepatectomy for colorectal liver metastases: which optimal definition and which predictive factors?
Oncologist. 2016; 21: 887-894
Assessing progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis.
Intern JAMA Med. 2018; 178: 1586-1596